Roivant Sciences Ltd.
Richard Pulik (CFO) sells ROIV shares
AI-generated summary
CFO Richard Pulik exercised options for 252,365 Common Shares at an average price of $3.85, worth $971,605.25. They also sold 300,000 Common Shares at an average price of $41.58, worth $12,473,271.90. After these transactions, Richard Pulik directly held 222,046 Common Shares.
Key facts
- Insider
- Richard Pulik · CFO
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | M · exercise or conversion of a derivative | +125,000 | $3.85 | $481,250.00 | 394,681 | Direct |
| Nov 10, 2026 | S · open-market saleFootnotes F1 | −125,000 | $41.20 | $5,150,000.00 | 269,681 | Direct |
| Nov 11, 2026 | M · exercise or conversion of a derivative | +127,365 | $3.85 | $490,355.25 | 397,046 | Direct |
| Nov 11, 2026 | S · open-market saleFootnotes F2 | −45,195 | $41.47 | $1,874,236.65 | 351,851 | Direct |
| Nov 11, 2026 | S · open-market saleFootnotes F3 | −82,170 | $42.03 | $3,453,605.10 | 269,681 | Direct |
| Nov 11, 2026 | S · open-market saleFootnotes F4 | −47,635 | $41.89 | $1,995,430.15 | 222,046 | Direct |
| Nov 10, 2026 | M · exercise or conversion of a derivativeStock Option (Right to Buy)Footnotes F5 | −125,000 | $0.00 | $0.00 | 615,000 | Direct |
| Nov 11, 2026 | M · exercise or conversion of a derivativeStock Option (Right to Buy)Footnotes F5 | −127,365 | $0.00 | $0.00 | 487,635 | Direct |
Footnotes
- F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.16 to $41.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
- F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.88 to $41.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
- F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.94 to $42.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
- F4 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.79 to $42.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
- F5 Reflects an award of stock options to purchase Common Shares that is fully vested.
More ROIV filings
- 4
Filed Nov 12, 2026
- 144
Filed Nov 12, 2026
- 144/A
Filed Nov 10, 2026
- 144/A
Filed Nov 10, 2026
- 144/A
Filed Nov 10, 2026
- 144
Filed Nov 10, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.